| | | Patients (no. of THA) | PPF | Dislocation (n, %) | AFL | SSI | Ossification | Other | RR | HS (CP/control) (years) |
| | Moore et al. [13], 2021 | 864 | 8/0.9% | 2.7% | 0 | 14/1.6% | 0 | 0 | 50/5.8% | 5 y: 94.2%/95.2% | | Moon et al. [14], 2020 | 2062 | N/A | N/A | N/A | 6/0.3% | N/A | Anaemia (30.2%) | N/A | N/A | | Molenaers et al. [15], 2017 | 29/37 THA | 1 (2.7%) | 5, 13.5% | 1 (2.7%) | 1 (2.7%) | 1 (2.7%) | | 4 (10.8%) | At 3 years: 89.2% | | Houdek et al. [16], 2017 | 41 | 0 | 3, 7.3% | 2 (4.8%) | 1 (2.4%) | 0 | DVT: 1 (2.4%) | 5/39 (12.8%) | 2 y: 92%, 5 y 88%, 10 y 81% | | Silverio et al. [17], 2016 | 12/16 THA | 1 (6.3%) | 0 | 0 | 0 | 6 (37.8%) | Anaemia (3.18.9%) | 3/16 (19%) | N/A | | Morin et al. [10], 2016 | 33/40 THA | 3 (7.5%) | 1, 2.5% | 2 (5%) | 2 (5%) | 0 | RDS (1.2.5%) | 6 (15%) | 5 y 85% | | King et al. [18], 2016 | 389 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | −1 y 2.6%, 3 y 4.7%, 5 y 6.4% | | Abousamra et al. [19], 2016 | 12 | 0 | 0 | 0 | 0 | 0 | LLD [7] | 0 | 90% at 3 years | | Yoon et al. [20], 2015 | 5 | 1 (20%) | 1, 20% | 0 | 0 | 0 | 0 | 0 | 0 revisions | | Alosh et al. [21], 2014 | 27/30 THA | 1 (8.3%) | 0 | 0 | 2 (16.6%) | 0 | Sacral ulcer (1, 8.3%) | 0 | | | Sanders et al. [22], 2013 | 10 | 1 (10%) | 0 | 0 | 0 | 0 | 0 | 1 (10%) | 3 y 90% | | Prosser et al. [9], 2012 | 19 | 1 (5%) | 2, 10% | 3 (15%) | 0 | 0 | RF (2.10%) | 3 (15%) | 8 y 85% | | Schoreder et al. [23], 2010 | 13/15 THA | 0 | 1, 7.7% | 2 (15.4%) | 1 (7.7%) | 0 | 0 | 4 (27%) | 10 y 73% | | Raphael et al. [8], 2010 | 56/59 THA | 1 (1.7%) | 5, 8.5% | 2 (3.3%) | 1 (1.7%) | 0 | | 9 (15.3%) | 2 y 95%, 10 y 85% | | Gavrakaptenovic et al. [26], 2007 | 31/45 THA | 2 (4.4%) | 3, 6.6% | 0 | 2 (4.4%) | 0 | 0 | 4 (8.8%) | N/A follow-up info | | Abu-Rajab et al. [27], 2007 | 15/21 THA | 0 | 1, 4.7% | 0 | 0 | 0 | Anaemia [2], N&V [4] | 1 (4.7%) | N/A follow-up | | Schorle et al. [28], 2006 | 16 | 1 (6.3%) | 1, 6.3% | 0 | 0 | 0 | N/A | 0 | N/A follow-up | | Weber et al. [29], 1999 | 16 | 2 (12.5%) | 0 | 1 (6.3%) | 0 | 0 | 0 | 3 (18.3%) | 82% at 10 years | | Gabos et al. [30], 1999 | 11/14 THA | 3 (21%) | 4, 28% | 2 (14%) | 0 | 5 (35%) | 0 | 0 | N/A follow-up | | Buly et al. [31], 1993 | 18/19 THA | 0 | 2, 10.5% | 0 | 0 | 0 | 0 | 2 (10.5%) | 86% at 10 years | | Root et al. [32], 1986 | 15 | 0 | 2, 13.3% | 1 (6.7%) | 0 | 0 | Bursitis (3.20%) | 1 (6.7%) | N/A |
|
|
RR: revision rate, SSI: surgical site of infection, PPF: periprosthetic fractures AFL: acetabular femoral loosening, HS: hip survivorship, LLD: leg length discrepancy, and RF: respiratory failure.
|
